posted on 2023-07-12, 14:20authored bySiddharth Mehra, Vanessa T. Garrido, Austin R. Dosch, Purushottam Lamichhane, Supriya Srinivasan, Samara P. Singh, Zhiqun Zhou, Iago De Castro Silva, Chandrashekar Joshi, Yuguang Ban, Jashodeep Datta, Eli Gilboa, Nipun B. Merchant, Nagaraj S. Nagathihalli
PD-L1 expression in Uro A or PI3Ki treated KPC cells.
Funding
HHS | NIH | National Cancer Institute (NCI)
Florida Department of Health
American Cancer Society (ACS)
History
ARTICLE ABSTRACT
Immunotherapeutic agents are ineffective against pancreatic cancer, mainly due to the immunosuppressive tumor microenvironment and stromal desmoplasia. Our current study demonstrates the therapeutic utility of a novel gut microbial metabolite, Uro A, to remodel the stromal-immune microenvironment and improve overall survival with anti-PD-1 therapy in pancreatic cancer.